ArticleJournal of neuroinflammation2026
Serum and CSF cytokine profile impact clinical phenotype in pediatric MOGAD.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Atypical MRI presentation of symmetrical thalamic and basal ganglia lesions in adult-onset MOG-IgG-associated disease: a case report.Frontiers in human neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundMyelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has a broad spectrum of clinical phenotypes, including acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), transverse myelitis (TM), and cerebral cortical encephalitis (CCE). Although these conditions exhibit diverse outcomes and require different treatment options for relapse prevention, no biomarkers have been identified to distinguish the clinical phenotypes. This study aimed to investigate the properties of cytokines and chemokines in the serum and cerebrospinal fluid (CSF) of patients with MOGAD and to determine whether they are associated with the clinical phenotype.
methodsIn this retrospective cohort study, we analyzed cytokines and chemokines in paired serum and CSF samples obtained during the acute phase before treatment from patients with MOG-IgG positivity, classified into five clinical phenotypes (ADEM, CCE, ON, TM, and “others”).
resultsOf the 50 patients diagnosed with MOGAD, 19 (38%) were diagnosed with ADEM, 9 (18%) with CCE, 3 (6%) with ON + TM, 9 (18%) with ON, and 10 (20%) with others. Overall, the CSF levels of Th17-related (including IL-6, CXCL8, G-CSF, IL-17, and IL-21) and B cell-related (including CXCL13, BAFF, and APRIL) cytokines/chemokines were elevated in pediatric patients with MOGAD compared with non-inflammatory neurological disease controls. Phenotype-stratified analyses of ADEM, CCE, and ON demonstrated higher CSF IL-6 and CXCL8 levels in encephalitic phenotypes (ADEM/CCE) than in ON. By contrast, no significant difference in the CSF-to-serum ratio (C/S ratio) for each cytokine was observed among the three phenotypes. Only the CXCL13 C/S ratio correlated with the ΔMOG-IgG C/S ratio.
conclusionPediatric patients with MOGAD showed limited phenotype-specific heterogeneity in their cytokine/chemokine profiles. Nevertheless, leptomeningeal inflammation was more prominent in patients with encephalitic presentations. Additionally, intrathecal MOG-IgG synthesis may be linked to intracranial inflammatory activity, which could inform future prospective studies using stratified treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.